Moderna price target lowered to $45 from $55 at Bernstein
Bernstein lowered the firm’s price target on Moderna (MRNA) to $45 from $55 and keeps a Market Perform rating on the shares. The firm cites the ...
Moderna (MRNA) Receives a Hold from Bernstein
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
There's no clear road for Rivian to outperform, says Bernstein's Daniel Roeska
Daniel Roeska, Bernstein U.S. automotive research, joins 'Power Lunch' to discuss whether Rivian can catch up to Tesla in the ...